

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

CHANGE OF AUTHORISED REPRESENTATIVE AND CHANGE OF BOOK CLOSURE PERIOD AND RECORD DATE

CHANGE OF AUTHORISED REPRESENTATIVE

The board of directors (the “**Board**”) of Sunshine Lake Pharma Co., Ltd. (the “**Company**”) hereby announces that Dr. LI Wenjia, the executive director and general manager of the Company, will cease to be one of the Company’s authorised representatives (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, with effect from 29 May 2026.

The Board further announces that Mr. CHENG Ching Kit, the company secretary of the Company, has been appointed as the Authorised Representative in place of Dr. LI Wenjia with effect from 29 May 2026. The Authorised Representative serves as the primary channel for communication between The Stock Exchange of Hong Kong Limited and the Company in relation to general listing matters.

CHANGE OF BOOK CLOSURE PERIOD AND RECORD DATE

Reference is made to the (i) 2025 annual report of the Company dated 30 April 2026 (“**Annual Report**”); and (ii) the notice (“**Notice**”) of the 2025 annual general meeting of the Company (the “**AGM**”) and the circular of the AGM (the “**Circular**”) both dated 28 May 2026 in relation to, among others, the book closure period of the register of members of the Company for determining the entitlement of shareholders of the Company to attend and vote at the AGM (“**Book Closure Period**”) and record date for the AGM (“**Record Date**”).

In relation to the Book Closure Period and the Record Date, the Company hereby announces that in accordance with the latest circumstances of the Company, the Book Closure Period will be revised and closed from Monday, 15 June 2026 to Thursday, 18 June 2026 (“**Revised Book Closure Period**”), both days inclusive, as stated in the Notice and Circular. During the Revised Book Closure Period, no transfer of shares of the Company (“**Shares**”) will be registered. The revised Record Date is therefore Monday, 15 June 2026.

Accordingly, as stated in the Notice and Circular, in order to be entitled to attend and vote at the AGM, holders of Shares whose transfers of shares have not been registered must lodge the transfer instruments together with the relevant share certificates to the Company's Board office at Securities Department, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang'an County, Dongguan, Guangdong Province, the PRC (for holders of domestic shares of the Company) or to the Company's H Share registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H Shares) no later than 4:30 p.m. on Friday, 12 June 2026.

Save for the aforesaid, all other information in the Annual Report, the Notice and the Circular remained unchanged.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
29 May 2026

As at the date of this announcement, the executive directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.